Nektar Therapeutics chief R&D officer Zalevsky sells $13,388 in shares By Investing.com

Jonathan Zalevsky, chief R&D officer at Nektar Therapeutics (), sold 186 shares of common stock on August 18, 2026, for a total value of $13,388. The shares were sold at prices ranging from $71.78 to $72.49, with a weighted average sale price of $71.98. The stock has since risen to $74.53, reflecting a remarkable 166% gain over the past year.

The transaction was executed to cover required tax withholding obligations in connection with the vesting of restricted stock units (RSUs) held by Mr. Zalevsky, and it does not represent a discretionary trade.

Following this transaction, Mr. Zalevsky beneficially owns 9,570 shares of Nektar Therapeutics common stock.According to InvestingPro analysis, the stock currently appears overvalued based on its Fair Value assessment. The company holds more cash than debt on its balance sheet but remains unprofitable. For deeper insights, investors can access a comprehensive Pro Research Report on NKTR, one of 1,400+ US equities covered.

In other recent news, Nektar Therapeutics reported its second-quarter financial results, showcasing a smaller-than-expected loss. The company posted a loss of $1.23 per share, surpassing analysts’ estimates of a $2.00 per share loss. However, Nektar’s revenue slightly missed expectations, coming in at $10.13 million compared to the anticipated $10.38 million. Despite the revenue miss, Nektar assured investors that its cash reserves are robust enough to support clinical development until 2028. These developments were part of the company’s ongoing journey toward commercialization. Additionally, it’s worth noting that the company’s stock saw a decline in after-hours trading following the earnings release. These recent developments highlight both the progress and challenges Nektar faces in its financial and operational strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.